Molecular modeling studies of human A3 adenosine antagonists: Structural homology and receptor docking

Journal of Chemical Information and Computer Sciences

Volumn 38, Issue 6, 1998, Pages 1239-1248

  Moro, Stefano ^a   Li, An Hu ^a   Jacobson, Kenneth A ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A3 RECEPTOR; ADENOSINE RECEPTOR;

ANIMAL; ARTICLE; BINDING SITE; BRAIN CORTEX; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; CHO CELL; DRUG ANTAGONISM; HAMSTER; HUMAN; IN VITRO STUDY; METABOLISM; NEOSTRIATUM; RADIOASSAY; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; BINDING SITES; CELL LINE; CEREBRAL CORTEX; CHO CELLS; CRICETINAE; HUMANS; MODELS, MOLECULAR; NEOSTRIATUM; RADIOLIGAND ASSAY; RATS; RECEPTOR, ADENOSINE A3; RECEPTORS, PURINERGIC P1; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0032199176     PISSN: 00952338     EISSN: None     Source Type: Journal    
DOI: 10.1021/ci980080e     Document Type: Article

References (56)

1. Jacobson, K. A.; van Rhee, A. M. Development of selective purinoceptor agonists and antagonists. In Purinergic Approaches in perimental Therapeutics; Jacobson, K. A., Jarvis, M. F., Eds.; Wiley: New York, 1997; Chapter 6, pp 101-128.
2. 3 adenosine receptor is the unique adenosine receptor which facilitates release of allergic mediators in mast cells. J. Biol. Chem. 1993, 268, 16887-16890.
3. 2+-ionophore-induced secretion in a rat mast-cell line. J. Pharmacol. Exp. Therap. 1996, 276, 837-845.
4. 3 adenosine receptors: design of selective ligands and therapeutic prospects. Drugs of the Future 1995, 20, 689-699.
5. 3 receptor stimulation and cerebral ischemia. Eur. J. Pharmacol. 1994, 263, 59-67.
6. 3 receptor antagonists and protection against cerebral ischemic damage in gerbils. Soc. Neurosci. Abstract 1997, 23, 1924.
7. 3 receptors in mast-cells. Trends Pharmacol. Sci. 1994, 15, 13-14.
8. 3 receptor stimulation inhibits migration of human eosinophils. J. Leukoc. Biol. 1997, 62, 465-468.
9. Ali, H.; Muller, C. E.; Daly, J. W.; Beaven, M. A. Methylxanthines block antigen-induced responces in RBL-2H3 cells independently of adenosine receptors or cyclic AMP: evidence for inhibition of antigen binding to IgE. J. Pharmacol. Exp. Ther. 1991, 258, 954-962.
10. 3 adenosine receptor. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 7432-7436.
11. 3 adenosine receptor. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 10365-10369.
12. Camaioni, E.; Costanzi, S.; Vittori, S.; Volpini, R.; Klotz, K.-N.; Cristalli, G. Adenosine receptor antagonists: new purine derivatives. Bioorg. Med. Chem. 1998, 6, 523-533.
13. Karton, Y.; Jiang, J. L.; Ji, X. D.; Melman, N.; Olah, M. E.; Stiles, G. L.; Jacobson, K. A. Synthesis and biological-activities of flavonoid derivatives as as adenosine receptor antagonists. J. Med. Chem. 1996, 39, 2293-2301.
14. Francis, J. E.; Cash, W. D.; Psychoyos, S.; Ghai, G.; Wenk, P.; Friedmann, R. C.; Atkins, C.; Warren, V.; Furness, P.; Hyun, J. L Structure-activity profile of a series of novel triazoloquinazoline adenosine antagonists. J. Med. Chem. 1988, 31, 1014-1020.
15. 3 receptor subtype. J. Med. Chem. 1996, 39, 4142-4148.
16. 3 receptors. J. Med. Chem. 1996, 39, 2980-2989.
17. 3 adenosine receptor antagonists. J. Med. Chem. 1996, 39, 4667-4675.
18. 3 adenosine receptor antagonists J. Med. Chem. 1998, 41, 3186-3201.
19. 3 adenosine receptor antagonists. Drug Devel. Res. 1996, 37, 131.
20. The program SYBYL 6.3 is available from TRIPOS Associates, St. Louis, MO, 1993.
21. Dewar, M. J. S. E.; Zoebisch, G.; Healy, E. F. AM1: A New General Purpose Quantum Mechanical Molecular Model. J. Am. Chem. Soc. 1985, 107, 3902-3909.
22. MOPAC 6.0 is available from Quantum Chemistry Program Exchange.
23. Gaussian 94, Revision C.2; Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Gill, P. M. W.; Johnson, B. G.; Robb, M. A.; Cheeseman, J. R.; Keith, T.; Petersson, G. A.; Montgomery, J. A.; Raghavachari, K.; Al-Laham, M. A.; Zakrzewski, V. G.; Ortiz, J. V.; Foresman, J. B.; Cioslowski, J.; Stefanov, B. B.; Nanayakkara, A.; Challacombe, M.; Peng, C. Y.; Ayala, P. Y.; Chen, W.; Wong, M. W.; Andres, J. L.; Replogle, E. S.; Gomperts, R.; Martin, R. L.; Fox, D. J.; Binkley, J. S.; Defrees, D.; Baker, J. J.; Stewart, J. P.; Head-Gordon, M.; Gonzalez, C.; Pople, J. A. Gaussian, Inc., Pittsburgh, 1995. Dobbs, K. D.; Hehre, W. J. Molecular orbital theory of the properties of inorganic d organometallic compounds 5. Extended basis sets for first-row transition metals. J. Comput. Chem. 1987, 8, 861-879.
24. Gaussian 94, Revision C.2; Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Gill, P. M. W.; Johnson, B. G.; Robb, M. A.; Cheeseman, J. R.; Keith, T.; Petersson, G. A.; Montgomery, J. A.; Raghavachari, K.; Al-Laham, M. A.; Zakrzewski, V. G.; Ortiz, J. V.; Foresman, J. B.; Cioslowski, J.; Stefanov, B. B.; Nanayakkara, A.; Challacombe, M.; Peng, C. Y.; Ayala, P. Y.; Chen, W.; Wong, M. W.; Andres, J. L.; Replogle, E. S.; Gomperts, R.; Martin, R. L.; Fox, D. J.; Binkley, J. S.; Defrees, D.; Baker, J. J.; Stewart, J. P.; Head-Gordon, M.; Gonzalez, C.; Pople, J. A. Gaussian, Inc., Pittsburgh, 1995. Dobbs, K. D.; Hehre, W. J. Molecular orbital theory of the properties of inorganic d organometallic compounds 5. Extended basis sets for first-row transition metals. J. Comput. Chem. 1987, 8, 861-879.
25. Dobbs, K. D.; Hehre, W. J. Molecular orbital theory of the properties of inorganic and organometallic compounds 5. Extended basis sets for first-row transition metals. J. Comput. Chem. 1987, 8, 861-879.
26. Chirlian, L. E.; Francl, M M. Atomic charges derived from electrostatic potentials: a detailed study. J. Comput. Chem. 1987, 8, 894-905.
27. Kearsley, S. K.; Smith, G. M. An Alternative Method for the Alignment of Molecular Structures: Maximizing Electrostatic and Steric Overlap. Tetrahedron Comput. Methodol. 1990, 3, 615-633.
28. The program PowerFit v. 1.0 is available from MicroSimulations, 478 Green Mountain Road, Mahwah, NJ 07430, 1996.
29. Mohamadi, F.; Richards, N. G. J.; Guida, W. C.; Liskamp, R.; Lipton, M.; Caufield, C.; Chang, G.; Hendrickson, T.; Still, W. C. Macro-Model-An Integrated Software System for Modeling Organic and Bioorganic Molecules using Molecular Mechanics. J. Comput. Chem. 1990, 11, 440-450.
30. van Rhee, A. M.; Fischer, B.; van Galen, P. J. M.; Jacobson, K. A. Modelling the P2Y purinoceptor using rhodopsin as template. Drug Design Discovery 1995, 13, 133-154.
31. 1 receptor: molecular modeling and site-directed mutagenesis as tools to identify agonist and antagonist recognition sites. J. Med. Chem. 1998, 41, 1456-1466.
32. Kyte, J.; Doolittle, R. F. A simple method for displaying the Hydrophobic character of a protein. J. Mol. Biol. 1982, 157, 105-132.
33. Weiner, S. J.; Kollman, P. A.; Nguyen, D. T.; Case, D. A. An allatom force field for simulation of protein and nucleic acids. J. Comput. Chem. 1986, 7, 230-252.
34. 6-phenylisopropyladenosine. Naunyn-Schmiedeberg's Arch. Pharmacol. 1980, 313, 179-187.
35. 2 receptors in rat brain tissue. J. Pharmacol. Exp. Therap. 1989, 251, 888-893.
36. 3 adenosine receptor. Mol. Pharmacol. 1994, 45, 978-982.
37. 50) of an enzyme reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
38. 1 receptor, based on steric, electrostatic, and hydrophobic properties. J. Med. Chem. 1990, 33, 1708-13.
39. Peet, N. P.; Lentz, N. L.; Meng, E. C.; Dudley, M. W.; Ogden, A. M.; Demeter, D. A.; Weintraub, H. J.; Bey, P. A novel synthesis of xanthines: support for a new binding mode for xanthines with respect to adenosine at adenosine receptors. J. Med. Chem. 1990, 33, 3127-3130.
40. Dooley, M. J.; Quinn, R. J. The Three Binding Domain Model of Adenosine Receptors Molecular Modeling Aspects. J. Med. Chem. 1992, 35, 211-216.
41. Quinn, R. J.; Dooley, M. J.; Escher, A.; Harden, F. A.; Jayasuriya, H. A Computer Generated Model of Adenosine Receptors Rationalising Binding and Selectivity of Receptor Ligands. Nucleos. Nucleot. 1991, 10, 1121-1124.
42. van Rhee, A. M.; Siddiqi, S. M.; Melman, N.; Shi, D.; Padgett, W. L.; Daly, J. W.; Jacobson, K. A. Tetrahydrobenzothiophenone derivatives as a novel class of adenosine receptor antagonists. J. Med. Chem. 1996, 39, 398-406.
43. 1 receptor antagonists. Bioorg. Med. Chem. 1996, 4, 917-921.
44. 1 ligands: requirements for receptor affinity. Bioorg. Med. Chem. 1996, 4, 923-934.
45. Humblet, C.; Marshall, G. R. Pharmacophore identification and receptor mapping. Ann. Rep. Med. Chem. 1980, 15, 267-276.
46. Hopfinger, A. J. Computer-assisted drug design. J. Med. Chem. 1985, 28, 1133-1139.
47. Gund, P.; Andose, J. D.; Rhodes, J. B.; Smith, G. M. Three-dimensional molecular modeling and drug design. Science 1980, 208, 1425-1431.
48. Herzyk, P.; Hubbard, R. E. Automated method for modeling seven-helix transmembrane receptors from experimental data. Biophys. J. 1995, 69, 2419-2442.
49. 3 adenosine receptor. Mol. Pharmacol. 1994, 45, 1101-1111.
50. Chiota, C.; Levitt, M.; Richardson, D. Helix to helix packing in proteins. J. Mol. Biol. 1981, 145, 215-250.
51. Sehertler, G. F.; Villa. C.; Henderson, R. Projection structure of rhodopsin. Nature 1993, 362, 770-772.
52. Urger, V. M.; Hargrave, P. A.; Baldwin, J. M.; Schertler, G. F. X. Arrangement of rhodopsin transmenbrane α-helices. Nature 1997, 389, 203-206.
53. Gouldson, P. R.; Snell, C. R.; Reynolds, C. A. A new approach to docking in the b2-adrenergic receptor that exploits the domain structure of G protein-coupled receptors. J. Med. Chem. 1997, 40, 3871-3886.
54. 2a adenosine receptor. J Biol. Chem. 1995, 270, 13987-13997.
55. 2A-adenosine receptors and the biogenic amine family. J. Med. Chem. 1997, 40, 2588-2595.
56. 2a adenosine receptors are required for ligand recognition. Mol. Pharmacol. 1996, 50, 512-521.